
AI at ASCO 2026: From Topic to Tool
AI tags 220 abstracts, the largest subtrack at ASCO 2026. Most of it is applied to concrete tasks; trial matching is where it meets drug development most directly.
Open AAI articleInsights
A unified article library combining public Apex AI articles with public oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword with official source links preserved.
Article library
A unified library of public Apex AI articles and public oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword; cards preserve public metadata and official source links only.
Source: All sources · Topic: All topics · 25 articles · 10 per page

AI tags 220 abstracts, the largest subtrack at ASCO 2026. Most of it is applied to concrete tasks; trial matching is where it meets drug development most directly.
Open AAI article
Prostate, bladder, and kidney cancer studies from ASCO 2026, organized by cancer, with trial sizes, hazard ratios, response rates, and data tables.
Open AAI article
Reading 50 advanced and metastatic prostate-cancer abstracts at AUA 2026: triplet gradient, PSMA-PET reclassification, PSMAddition, survivorship-as-section, and what is still missing.
Open AAI article
CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis, according to a study published in Clinical Cancer Research. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
621 abstracts, one in five. Single-port leads, LLMs arrive, and the AI-robot intersection is nearly empty.
Open AAI article
The AACR Annual Meeting 2026 featured a spectacular display of the progress that is being made against cancer due to your tremendous efforts. All of you—cancer researchers, clinicians, other health care profes... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
The American Association for Cancer Research (AACR) today thanked Emerging Frontiers in Oncology (EFO) for its support of the cancer research workforce through fundraising associated with the 8th Annual Emergi... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
358 HNSCC abstracts, new therapeutic architectures, diversifying biomarkers, and three bets against checkpoint-refractory disease.
Open AAI article
Katerina A. Politi, PhD, identified takeaways emerging from presentations in basic and translational science, including that fundamental insights into cancer biology are revealing new strategies to treat cance... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
Katayoun Rezvani, MD, PhD, chaired the session, which shone a light on radiopharmaceuticals, next-generation biologics, and cellular immunotherapy as groundbreaking therapeutic modalities for cancer, with a fo... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source